PerformRx receives PBM accreditation from URAC
PHILADELPHIA A full-service pharmacy benefit manager received its second accreditation from an independent, nonprofit healthcare-accrediting organization.
PerformRx said that its pharmacy benefit management accreditation from URAC indicated that PerformRx’s PBM business demonstrated a commitment to quality services. “This accreditation serves as a clear sign that PerformRx is committed to providing the best possible service to our existing and future customers,” said Mesfin Tegenu, PerformRx president. “The URAC evaluation is an incredibly rigorous process that evaluates the organization at all levels, and to wear the URAC seal is a mark of distinction for our company.”
In conjunction with its PBM accreditation, PerformRx also applied for URAC’s drug therapy management accreditation. PerformRx’s DTM program improves therapeutic outcomes for members by evaluating drug dose, method of delivery, cost effectiveness and other factors, the company said, adding that obtaining the DTM accreditation will allow PerformRx to demonstrate the high quality and effectiveness of its DTM program.
CHPA names Melville its new president
WASHINGTON —Scott Melville has been named the new president of the Consumer Healthcare Products Association, succeeding Linda Suydam, who is retiring after eight years with CHPA. The news becomes official Nov. 1.
Prior to the announcement, Melville served as SVP government affairs and general counsel for the Healthcare Distribution Management Association. Before joining HDMA, Melville was as an attorney and head of government relations for Cephalon. A veteran facilitator, familiar with health care and the vital role over-the-counter medicines and natural products play in today’s healthcare system, Melville also is a former staffer for Rep. Jerry Lewis, R-Calif.
At CHPA, Melville will have an opportunity to bring all of his decades of experience as a healthcare sector advocate to bear. With healthcare reform on the line and millions of baby boomers hitting their 60s, CHPA chairman Christopher DeWolf said that Melville’s “experience in public policy, coalition building and working with government officials and key stakeholders will be invaluable in guiding the industry through the rapidly changing healthcare environment.”
Study: Consumers stay loyal to Tylenol, despite recent McNeil problems
PHILADELPHIA —According to a recent study released by the Relational Capital Group, consumer purchase intent and brand loyalty for Tylenol still is high despite the recent spate of Tylenol product recalls. According to the study, 76% of consumers reported positive purchase intent, and 67% reported positive brand loyalty for Tylenol.
That ought to be good news for Johnson & Johnson. During a hearing held earlier this month, J&J chairman and CEO Bill Weldon noted that McNeil Consumer would begin resupplying the recalled Tylenol products in the coming weeks and ramping up to traditional supply levels through first quarter 2011.
“As you look at the Tylenol situation, consumers are interpreting [McNeil’s] production problems as a short-term lapse in competence, rather than a significant change in what their intentions are toward consumers,” Chris Malone, chief advisory officer of the Relational Capital Group, told Drug Store News. “When we look at the Tylenol brand, it appears that there is such a long track record of reliability and trust, and a deep reservoir of good will,” he said, that consumers generally don’t believe J&J intentionally cut any corners in an effort to boost profits. In contrast, consumers generally identified both a lapse in competence and a dishonest pattern in the behavior of BP over the course of that company’s oil spill crisis.